NeuraWorx closes oversubscribed seed led by Nexus NeuroTech Ventures for CNS therapy platform
Summary
NeuraWorx closed an oversubscribed seed round led by Nexus NeuroTech Ventures for their CNS neurotechnology therapy platform. Nexus NeuroTech — the specialist neurotech fund that also backed Beacon Biosignals and Ampa Health — leading an oversubscribed seed signals strong conviction in NeuraWorx's approach. Details of the specific technology and indication remain undisclosed, but Nexus NeuroTech's portfolio pattern suggests neurodiagnostic or biomarker-guided therapeutic development.
Why it matters
Nexus NeuroTech Ventures co-investing in three CNS companies (Beacon Biosignals, Ampa Health, NeuraWorx) is building a portfolio strategy around objective neural biomarkers for both diagnostics and therapy guidance — the precision medicine infrastructure layer for the next generation of neurotech therapeutics.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial